MedTrace Logo

Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity Using Metabolomics

NCT01215214 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-02-23

No results posted yet for this study

Summary

Identification and evaluation of endogenous markers for the assessment of CYP3A activity using metabolomics.

Conditions

  • Healthy

Interventions

DRUG

midazolam

midazolam: 3mg iv

Sponsors & Collaborators

  • Ministry of Education Science and Technology, Korea

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Joo-Youn Cho, PhD · Seoul National University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2010-11-30
Completion
2011-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01215214 on ClinicalTrials.gov